Literature DB >> 24850491

Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.

Muhammad Taimur Malik1, Brian C Healy1, Leslie A Benson1, Pia Kivisakk1, Alexander Musallam1, Howard L Weiner1, Tanuja Chitnis2.   

Abstract

OBJECTIVE: To identify clinical and demographic features associated with the severity and recovery from acute optic neuritis (AON) episodes in patients with multiple sclerosis (MS).
METHODS: Adult (n = 253) and pediatric (n = 38) patients whose first symptom was AON were identified from our MS database. Severity measured by loss of visual acuity (mild attack ≤20/40, moderate attack 20/50-20/190, and severe attack ≥20/200) and recovery in visual acuity at 1 year after the attack (complete recovery ≤20/20, fair recovery 20/40, and poor recovery ≥20/50) were recorded. Demographic and clinical features associated with attack severity and recovery were identified using proportional odds logistic regression. For another group of patients, blood samples were available within 6 months of an AON attack. In this group, the impact of vitamin D level on the severity/recovery was also assessed.
RESULTS: Men (adjusted odds ratio [OR] = 2.28, p = 0.03) and subjects with severe attacks (adjusted OR = 5.24, p < 0.001) had worse recovery. AON severity was similar between the pediatric and adult subjects, but recovery was significantly better in pediatric subjects in the unadjusted analysis (p = 0.041) and the analysis adjusted for sex (p = 0.029). Season-adjusted vitamin D level was significantly associated with attack severity (OR for 10-U increase in vitamin D level = 0.47; 95% confidence interval: 0.32, 0.68; p < 0.001). Vitamin D level was not associated with recovery from the attack (p = 0.98) in univariate analysis or after accounting for attack severity (p = 0.10).
CONCLUSION: Vitamin D levels affect AON severity, whereas younger age, attack severity, and male sex affect AON recovery. Underlying mechanisms and potential therapeutic targets may identify new measures to mitigate disability accrual in MS.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850491      PMCID: PMC4113460          DOI: 10.1212/WNL.0000000000000524

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

2.  Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.

Authors:  F Brusaferri; L Candelise
Journal:  J Neurol       Date:  2000-06       Impact factor: 4.849

3.  Age-related disability in multiple sclerosis.

Authors:  Maria Trojano; Maria Liguori; Giovanni Bosco Zimatore; Roberto Bugarini; Carlo Avolio; Damiano Paolicelli; Fabrizio Giuliani; Francesca De Robertis; Maria Giovanna Marrosu; Paolo Livrea
Journal:  Ann Neurol       Date:  2002-04       Impact factor: 10.422

4.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

Authors:  Mark P Gorman; Brian C Healy; Mariann Polgar-Turcsanyi; Tanuja Chitnis
Journal:  Arch Neurol       Date:  2009-01

5.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

6.  Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

Authors:  O Kantarci; A Siva; M Eraksoy; R Karabudak; N Sütlaş; J Ağaoğlu; F Turan; M Ozmenoğlu; E Toğrul; M Demirkiran
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

Review 7.  Prognostic factors in multiple sclerosis.

Authors:  Roberto Bergamaschi
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

8.  Natural history of multiple sclerosis with childhood onset.

Authors:  Christel Renoux; Sandra Vukusic; Yann Mikaeloff; Gilles Edan; Michel Clanet; Bénédicte Dubois; Marc Debouverie; Bruno Brochet; Christine Lebrun-Frenay; Jean Pelletier; Thibault Moreau; Catherine Lubetzki; Patrick Vermersch; Etienne Roullet; Laurent Magy; Marc Tardieu; Samy Suissa; Christian Confavreux
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

9.  The onset location of multiple sclerosis predicts the location of subsequent relapses.

Authors:  E M Mowry; S Deen; I Malikova; J Pelletier; P Bacchetti; E Waubant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-12-09       Impact factor: 10.154

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  13 in total

1.  Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis.

Authors:  Carmen Tur; Olivia Goodkin; Daniel R Altmann; Thomas M Jenkins; Katherine Miszkiel; Alessia Mirigliani; Camilla Fini; Claudia A M Gandini Wheeler-Kingshott; Alan J Thompson; Olga Ciccarelli; Ahmed T Toosy
Journal:  Brain       Date:  2016-02-17       Impact factor: 13.501

2.  The optic nerve lamina region is a neural progenitor cell niche.

Authors:  S L Bernstein; Y Guo; C Kerr; R J Fawcett; J H Stern; S Temple; Z Mehrabian
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-28       Impact factor: 11.205

Review 3.  Some recent advances in multiple sclerosis.

Authors:  Claire McCarthy; John Thorpe
Journal:  J Neurol       Date:  2016-04-25       Impact factor: 4.849

4.  25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis.

Authors:  Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

5.  Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.

Authors:  Maureen A Mealy; Anna Whetstone; Gunes Orman; Izlem Izbudak; Peter A Calabresi; Michael Levy
Journal:  J Neurol Sci       Date:  2015-05-17       Impact factor: 3.181

6.  Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.

Authors:  Giovanna Borriello; Carlo Pozzilli
Journal:  Neurol Sci       Date:  2021-03-10       Impact factor: 3.307

7.  Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.

Authors:  Amy T Waldman; Salim Chahin; Amy M Lavery; Geraldine Liu; Brenda L Banwell; Grant T Liu; Laura J Balcer
Journal:  Mult Scler Relat Disord       Date:  2016-08-26       Impact factor: 4.339

8.  Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis: A Cross-sectional Study.

Authors:  Justin R Abbatemarco; Robert J Fox; Hong Li; Robert A Bermel; Daniel Ontaneda
Journal:  Int J MS Care       Date:  2020-04-28

9.  Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability.

Authors:  Marinos G Sotiropoulos; Hrishikesh Lokhande; Brian C Healy; Mariann Polgar-Turcsanyi; Bonnie I Glanz; Rohit Bakshi; Howard L Weiner; Tanuja Chitnis
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-05-28

Review 10.  Acute optic neuritis: Unmet clinical needs and model for new therapies.

Authors:  Steven L Galetta; Pablo Villoslada; Netta Levin; Kenneth Shindler; Hiroshi Ishikawa; Edward Parr; Diego Cadavid; Laura J Balcer
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.